MedPath

RECORDATI

RECORDATI logo
🇮🇹Italy
Ownership
Private
Established
1926-01-01
Employees
501
Market Cap
$12B
Website
https://www.recordati.com.tr
Clinical Trials
Related News

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Phase 2
Recruiting
Conditions
Post-Bariatric Hypoglycemia
Interventions
First Posted Date
2023-07-03
Last Posted Date
2025-06-03
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
72
Registration Number
NCT05928390
Locations
🇺🇸

Stanford University School of Medicine, Endocrinology, 800 Welch Road,, Palo Alto, California, United States

🇺🇸

Georgia Clinical Research, LLC, 2878 Five Forks Trickum SW, Suite 2A, Lawrenceville, Georgia, United States

🇺🇸

Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 28 locations

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

Completed
Conditions
Cushing's Syndrome
First Posted Date
2022-12-01
Last Posted Date
2025-02-10
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
103
Registration Number
NCT05633953
Locations
🇫🇷

Hôpital Haut-Lévèque, Pessac, France

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
Conditions
Endogenous Cushing's Syndrome
Interventions
First Posted Date
2022-05-19
Last Posted Date
2024-07-16
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
206
Registration Number
NCT05382156
Locations
🇺🇸

Barrow Neurological Institute, Phoenix, Arizona, United States

🇺🇸

Emory University School, Atlanta, Georgia, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 40 locations

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Phase 2
Recruiting
Conditions
Cushing Syndrome
Interventions
First Posted Date
2018-10-17
Last Posted Date
2025-05-14
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
12
Registration Number
NCT03708900
Locations
🇺🇸

University of California San Francisco UCSF, San Francisco, California, United States

🇺🇸

National Institute of Child Health and Human Development, Bethesda, Maryland, United States

🇧🇪

UZ Brussel, Jette, Brussel, Belgium

and more 9 locations

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Phase 2
Completed
Conditions
Cushing's Syndrome
Interventions
First Posted Date
2018-07-30
Last Posted Date
2024-12-18
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
127
Registration Number
NCT03606408
Locations
🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Emory University School of Medicine G2304 - C2301, Atlanta, Georgia, United States

🇺🇸

Northwestern University SC - LCI699C2301, Chicago, Illinois, United States

and more 53 locations

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Phase 1
Completed
Conditions
Neurogenic Detrusor Overactivity
Interventions
Drug: placebo
Drug: Rec 0/0438 1 mg or Rec 0/0438 2 mg
First Posted Date
2018-03-29
Last Posted Date
2021-01-29
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
42
Registration Number
NCT03482037
Locations
🇵🇹

Recordati Investigative Site, Porto, Portugal

🇫🇷

Department of Urology, Academic hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne Universités, Paris, France

🇫🇷

Centre Hospitalier Lyon Sud Unité de Pharmacie Clinique Oncologique (essai clinique) Pavillon Marcel Bérard - Bât. 1G, Pierre-Bénite, France

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Completed
Conditions
Cushings Disease
Interventions
First Posted Date
2014-12-08
Last Posted Date
2024-10-14
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
152
Registration Number
NCT02310269
Locations
🇨🇦

Centre de recherche du CHUM CRCHUM, Montreal, Quebec, Canada

🇨🇦

CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada

🇨🇦

CHUL Centre de recherche du CHU, Quebec, Canada

and more 51 locations

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Phase 3
Terminated
Conditions
Lower Urinary Tract Symptoms
Interventions
First Posted Date
2013-12-06
Last Posted Date
2022-05-26
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
104
Registration Number
NCT02003742
Locations
🇩🇪

Klinikum der Ludwig-Maximilians-universität München, Munich, Germany

🇮🇹

Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy

🇵🇱

Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland

and more 2 locations

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4
Completed
Conditions
Acromegaly
Pituitary Tumors
Ectopic ACTH Secreting (EAS) Tumors
Melanoma Negative for bRAF
Cushing's Disease
Neuroendocrine Tumors
Prostate Cancer
Melanoma Negative for nRAS
Dumping Syndrome
Interventions
First Posted Date
2013-02-20
Last Posted Date
2024-10-01
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
337
Registration Number
NCT01794793
Locations
🇺🇸

Ximed Research SC - SOM230B2412, La Jolla, California, United States

🇺🇸

Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States

🇺🇸

Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States

and more 6 locations

Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia

Phase 4
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
First Posted Date
2012-12-31
Last Posted Date
2014-04-29
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
1036
Registration Number
NCT01757769
Locations
🇮🇹

Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy